Cargando…

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

OBJECTIVE: The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome proliferator–activated receptor (PPAR)-α/δ agonist, on peripheral and hepatic insulin sensitivity. RESEARCH DESIGN AND METHODS: Twenty-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cariou, Bertrand, Hanf, Rémy, Lambert-Porcheron, Stéphanie, Zaïr, Yassine, Sauvinet, Valérie, Noël, Benoit, Flet, Laurent, Vidal, Hubert, Staels, Bart, Laville, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781493/ https://www.ncbi.nlm.nih.gov/pubmed/23715754 http://dx.doi.org/10.2337/dc12-2012

Ejemplares similares

Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
por: Cariou, Bertrand, et al.
Publicado: (2011)

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model
por: Liu, Linfu, et al.
Publicado: (2020)

Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults
por: Cariou, Bertrand, et al.
Publicado: (2011)

Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(®)
por: Hachem, Mayssa, et al.
Publicado: (2020)

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
por: Lee, Mi Young, et al.
Publicado: (2012)

Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction
por: Park, Jeong Rang, et al.
Publicado: (2016)

CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review
por: Breyton, Anne-Esther, et al.
Publicado: (2021)

505 Verdades publicitarias /
por: Pratt Gaballí, Pedro
Publicado: (2001)

Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ(1)-HDL, α-HDL, and triglyceride-rich lipoproteins
por: Chétiveaux, Maud, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor δ Agonist, HPP593, Prevents Renal Necrosis under Chronic Ischemia
por: Fedorova, Larisa V., et al.
Publicado: (2013)

Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor δ Agonist
por: Lee, Su-Jeong, et al.
Publicado: (2018)

Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor δ Agonist Improves Cellular Bioenergetics
por: D’Annibale, Olivia M., et al.
Publicado: (2022)

Grape Polyphenols Prevent Fructose-Induced Oxidative Stress and Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients
por: Hokayem, Marie, et al.
Publicado: (2013)

Transcriptional Regulation of Δ6-Desaturase by Peroxisome Proliferative-Activated Receptor δ Agonist in Human Pancreatic Cancer Cells: Role of MEK/ERK1/2 Pathway
por: Darabi, Maryam, et al.
Publicado: (2013)

Postprandial Endotoxin Transporters LBP and sCD14 Differ in Obese vs. Overweight and Normal Weight Men during Fat-Rich Meal Digestion
por: Laugerette, Fabienne, et al.
Publicado: (2020)

SUN-505 The Invincible Parathyroid Gland
por: Mayorga, Mabel, et al.
Publicado: (2019)

The Natural Protective Mechanism Against Hyperglycemia in Vascular Endothelial Cells: Roles of the Lipid Peroxidation Product 4-Hydroxydodecadienal and Peroxisome Proliferator–Activated Receptor δ
por: Riahi, Yael, et al.
Publicado: (2010)

Targeting Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) for Cancer Chemoprevention
por: Peters, Jeffrey M., et al.
Publicado: (2015)

Polyphenol Supplementation Did Not Affect Insulin Sensitivity and Fat Deposition During One-Month Overfeeding in Randomized Placebo-Controlled Trials in Men and in Women
por: Segrestin, Bérénice, et al.
Publicado: (2022)

I4 Hotspot: runs 505 and 508
por: Risselada, Thys
Publicado: (1974)

SUN-505 Total Thyroidectomy in Severe Hyperthyroidism
por: Del Alamo, Cynthia Diana Zegarra, et al.
Publicado: (2020)

505 Assessing the Accessibility of CTSA Training Resources
por: Ebanks, Yasheca T, et al.
Publicado: (2022)

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways
por: Klein, Kevin, et al.
Publicado: (2021)

Phenotypic and Proteomic Analysis of the Aspergillus fumigatus ΔPrtT, ΔXprG and ΔXprG/ΔPrtT Protease-Deficient Mutants
por: Shemesh, Einav, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor β/δ in the Brain: Facts and Hypothesis
por: Hall, M. G., et al.
Publicado: (2008)

Peroxisome Proliferator-Activated Receptor -β/δ, -γ Agonists and Resveratrol Modulate Hypoxia Induced Changes in Nuclear Receptor Activators of Muscle Oxidative Metabolism
por: Regnault, Timothy R. H., et al.
Publicado: (2010)

Unraveling the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) expression in colon carcinogenesis
por: Peters, Jeffrey M., et al.
Publicado: (2019)

Endurance Training with or without Glucose-Fructose Ingestion: Effects on Lactate Metabolism Assessed in a Randomized Clinical Trial on Sedentary Men
por: Rosset, Robin, et al.
Publicado: (2017)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
por: Morrell, Ruth, et al.
Publicado: (2013)

POS-505 THYROID DISEASE IN TIME OF COVID19
por: Ajimi, K., et al.
Publicado: (2022)

SAT505 Pericardial Effusion as The Primary Manifestation of Hypothyroidism
por: Lai, William, et al.
Publicado: (2023)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study
por: Wargny, Matthieu, et al.
Publicado: (2019)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma
por: Leone, Patrizia, et al.
Publicado: (2023)

Metabolic Functions of Peroxisome Proliferator-Activated Receptor β/δ in Skeletal Muscle
por: Gaudel, Céline, et al.
Publicado: (2007)

Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation
por: Pollock, Claire B., et al.
Publicado: (2010)

Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations
por: Espinosa-Jiménez, Triana, et al.
Publicado: (2022)

Genomewide Analyses Define Different Modes of Transcriptional Regulation by Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ)
por: Adhikary, Till, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kp6kmn9q6pd4ucsd1a656arm2v